Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.33 |
| ▸ | CDK2 | P24941 | 5/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.33 |
| ▸ | TOP2A | P11388 | 2/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1441784 | 1.00 | CHRM3 (0.35) | CHRM3DPP4CCNE1CDK2L3MBTL1 | |
| SCHEMBL954528 | 1.00 | CHRM3 (0.35) | CHRM3DPP4CCNE1CDK2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL28057619 | 0.98 | DPP4 (0.35) | CHRM3DPP4CCNE1CDK2L3MBTL1 | |
| Methane SCHEMBL27926432 | 0.98 | CHRM3 (0.34) | CHRM3DPP4CCNE1CDK2L3MBTL1 | |
| Bicarbonate SCHEMBL1532914 | 0.97 | CHRM3 (0.36) | CHRM3DPP4CCNE1CDK2L3MBTL1 | |
| SCHEMBL17513413 | 0.90 | SLC6A1 (0.37) | DPP4CCNE1CDK2L3MBTL1GSK3B | |
| SCHEMBL740082 | 0.90 | SLC6A1 (0.37) | DPP4CCNE1CDK2L3MBTL1GSK3B | |
| SCHEMBL3698542 | 0.90 | SLC6A1 (0.37) | DPP4CCNE1CDK2L3MBTL1GSK3B | |
| SCHEMBL854419 | 0.89 | CHRM3 (0.42) | CHRM3DPP4CCNE1CDK2GSK3B | |
| SCHEMBL28493616 | 0.89 | EPHX1 (0.39) | DPP4CCNE1CDK2L3MBTL1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102245599-B | Novel 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS INC | 2014-05-14 | — | — | CN | claimed |
| CN-103402997-A | Diaminopyrimidine derivatives and process for preparing same | YUHAN INC | 2013-11-20 | — | — | CN | claimed |
| US-20240190864-A1 | Bruton's Tyrosine Kinase (BTK) INHIBITOR AND APPLICATION THEREOF | YA THERAPEUTICS INC (CN) | 2024-06-13 | — | — | US | disclosed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| EP-3999498-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Kinnate Biopharma Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2022-04-28 | — | — | US | disclosed |
| EP-3409672-B1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2021-12-08 | — | — | EP | disclosed |
| US-11059825-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| WO-2021011796-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-10723742-B2 | Biphenyl compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
| CN-101039672-A | Chemical compounds | SMITHKLINE BEECHAM CORP (US) | 2007-09-19 | — | — | CN | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-09-14 | — | — | US | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1614419-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-01-11 | — | — | EP | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | CHRM3 2337/4885DPP4 4105/4885CCNE1 361/4885 |
| US-10723742-B2 | Biphenyl compound or salt thereof | KDM1B, BMI1, HDAC1 | CHRM3 4741/4885DPP4 2612/4885CCNE1 3168/4885 |
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | CHRM3 153/4885DPP4 4424/4885CCNE1 860/4885 |
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | RB1, ALDH1A2, NR2E3 | CHRM3 591/4885DPP4 1780/4885CCNE1 1464/4885 |
| US-11059825-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | CHRM3 618/4885DPP4 1996/4885CCNE1 3775/4885 |
| US-20240190864-A1 | Bruton's Tyrosine Kinase (BTK) INHIBITOR AND APPLICATION THEREOF | BTK, SYK, LYN | CHRM3 4307/4885DPP4 3288/4885CCNE1 2145/4885 |
| US-11834452-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | CHRM3 618/4885DPP4 1996/4885CCNE1 3775/4885 |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | CHRM3 2607/4885DPP4 1128/4885CCNE1 1183/4885 |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | CHRM3 618/4885DPP4 1996/4885CCNE1 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.